MagForce merges existing share classes

Berlin, Germany, June 20, 2013 – MagForce AG (Frankfurt, Entry Standard, XETRA: MF6), a leading medical device company in the field of nanomedicine focused on oncology, announced today that the two different existing share classes have been prematurely merged, effective June 20, 2013. The new shares issued in the context of the capital increase early 2013 with ISIN DE000A1R1KE3 (WKN A1R1KE) and the old shares with ISIN DE000A0HGQF5 (WKN A0HGQF) will immediately be traded under the security details of the old shares: ISIN DE000A0HGQF5 (WKN A0HGQF). New shares have been suspended for trading accordingly on the morning of June 20, 2013. It is expected that shares will be available for trading late in the day under WKN A0HGQF.

About MagForce AG

MagForce AG is a leading medical device company in the field of nanomedicine in oncology. The Company’s proprietary, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm®, NanoPlan®, and NanoActivator™ are trademarks of MagForce AG in selected countries. For more information, please visit www.magforce.com.

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as “expects”, “aims”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or “will”. Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.